Ein Januskopf?

Archambeau PL, Hollenhorst RW, Rucker CW (1965) Posterior uveitis as a manifestation of multiple sclerosis. Mayo Clin Proc 40:544–551 Becker MD, Heiligenhaus A, Hudde T et al (2005) Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 89:1254–1257 Belardelli F, Gresser I (1996) The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 17:369–372 BenEzra D, Cohen E (1986) Treatment and visual prognosis in Behçet’s disease. Br J Ophthalmol 70:589–592 Biousse V et al (1999) Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 52(1):179–181 Bodaghi B, Gendron G, Wechsler B et al (2007) Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrosprective monocentric study of 45 patients. Br J Ophthalmol 91:335–339 Brasnu E, Wechsler B, Bron A et al (2005) Efficacy of interferon-alpha for the treatment of Kaposi’s sarcoma herpesvirus-associated uveitis. Am J Ophthalmol 140:746–748 Conlon KC, Urba WJ, Smith JW et al (1990) Exacerbation of symptoms of autoimmune disease in patients receiving interferon-alpha therapy. Cancer 65:2237–2242 Deuter CME, Kötter I, Günaydin I et al (2006) Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 26:786–791 Deuter CM, Kötter I, Günaydin I et al (2009) Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 93:906–913 Deuter CM, Zierhut M, Möhle A et al (2010) Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum 62(9):2796–2805 Doycheva D, Deuter CME, Stübiger N et al (2009) Interferon-alpha associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol 247:675–680 Gillies MC, Su T (1995) Interferon alpha2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvasc Res 49:277–288 Green AR, Vassilou GS, Curtin N et al (2004) Management of the myeloproliferative disorders: distinguishing data from dogma. Hematol J 5:126–132 Gueudry J, Wechsler B, Terrada C et al (2008) Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet’s disease. Am J Ophthalmol 146:837–844 Guillaume-Czitrom E, Berger C, Pajot C et al (2007) Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet’s disease. Rheumatology 46:1570–1573 Hamuryudan V, Ozyazgan Y, Fresko Y et al (2002) Interferon alfa combined with azathioprine for the uveitis of Behcet’s disease: an open study. Isr Med Assoc J 4:928–930 Hatemi G, Bang D, Bodaghi B et al (2008) EULAR recommendations for the management of Behçet’s disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 67:1656–1662 Hoffmann A, Kim E, Krueger GR et al (1994) Bone marrow hypoplasia and fibrosis following interferon treatment. In Viva 8:605–612 Hurst EA, Mauro T (2005) Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Arch Dermatol 141:865–868 Imrie FR, Dick AD (2007) Biologicals in the treatment of uveitis. Curr Opin Ophthalmol 18:481–486 International Study Group for Behçet’s disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080 Isaacs A, Lindemann J (1957) Viral interference. I. The interferon. Proc R Soc Lond B Biol Sci 147(927):258–267 Kötter I, Zierhut M, Eckstein AK et al (2003) Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423–431 Kötter I, Günaydin I, Zierhut M et al (2004) The use of interferon alpha in Behcet’s disease: review of the literature. Semin Arthritis Rheum 33:320–335 Krause L, Altenburg A, Pleyer U et al (2008) Longterm visual prognosis of patients with ocular Adamantiades-Behçet’s disease treated with interferon-alfa-2a. J Rheumatol 35(5):896–903 Mackensen F, Regina M, Becker MD (2009) Interferons an their potential in the treatment of ocular inflammation. Clin Experiment Ophthalmol 3:559–566 Mackensen F et al (2010) Long-term results of a monocentric controlled clinical trial comparing interferon beta with methotrexate in the treatment of uveitis macular edema. ARVO Abstract 2916 Mishima S, Masuda K, Izawa Y, Mochizuki M (1979) Behçet’s disease in Japan: Ophthalmologic aspects. Tr AM Ophth Soc LXXVII:225–279 Montvale NJ (2000) Physicans desk reference. Medical Economics Company, Montvale, NJ, S 2654–2658, 2808–2817 Okada AA, Keino H, Fukai T (1998) Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 6:209–210 Okada AA (2005) Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 13:335–351 Okada H, Pollack IF (2004) Cytokine gene therapy for malignant glioma. Expert Opin Biol Ther 4:1609–1620 Plskova J, Greiner K, Muckersie E et al (2006) Interferon-alpha: a key factor in autoimmune disease? Invest Ophthalmol Vis Sci 47(9):3946–3950 Plskova J, Greiner K, Forrester JV (2007) Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 144(1):55–61 Purvin VA (1995) Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 113(8):1041–1044 Saadeh S, Davis GL (2004) The evolving treatment of chronic hepatitis C: where we stand a decade out. Cleve Clin J Med 71:3–7 Sobaci G, Bayraktar Z, Bayer A (2005) Interferon alpha-2a treatment for serpinginous choroiditis. Ocul Immunol Inflamm 13:59–66 Sobaci G, Erdem U, Durukan AH et al (2010) Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet’s uveitis refractory to conventional treatments. Ophthalmology 117:1430–1435 Saito H, Ebinuma G, Satoh H et al (2000) Immunological and virological predictors of outcome during interferon-alpha therapy of chronic hepatitis C. J Viral Hepat 7:64–74 Stoutenburg JP, Schrope B, Kaufmann HL (2004) Adjuvant therapy for malignant melanoma. Expert Rev Anticancer Ther 8:823–835 Stübiger N, Kötter I, Zierhut M (2000) Complete regression of retinal neovascularisation after therapy with interferon alfa in Behcet’s disease. Br J Ophthalmol 84:1437–1438 Stübiger N, Kötter I, Deuter CM et al (2001) Behcet’s disease: uveitis-therapy with interferon alpha2a – prospective clinical study in 33 patients. Klin Monatsbl Augenheilkd 528:768–773 Stübiger N, Crane I, Kötter I et al (2003) Interferon alpha2a in IRBP-derived peptide induced EAU – part I. Adv Exp Med Biol 528:537–540 Suzuki J, Sakai J, Okada AA et al (2002) Oral administration of interferon-beta suppresses experimental autoimmune uveoretinitis. Graefes Arch Clin Exp Ophthalmol 240:314–321 Treusch M, Vonthein R, Baur M et al (2004) Influence of human recombinant interferon-alpah2a (rhIFNalpha2a) on altered lymphocyte subpopulations and monocytes in Behçet’s disease. Rheumatology 43(10):1275–1282 Tsambaos D, Eichelberg D, Goos M (1986) Behçet’s syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 278:335–336 Tugal-Tutgun I, Guney-Tefekli E, Urgancioglu M (2006) Results of interferon-alfa therapy in patients with Behçet’s uveitis. Graefes Arch Clin Exp Ophthalmol 244:1692–1695 Usui Y, Takeuchi M, Hattori T et al (2009) Suppression of experimental autoimmune uveoretinitis by regulatory dentritic cells in mice. Arch Ophthalmol 127:514–519 Vandenbark AA, Huan J, Agotsch M et al (2009) Interferon-beta-1a treatment increases CD56(bright) natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 215(1–2):125–128 Wang W, Edington HD, Rao UN et al (2008) Effects of high dose IFN alpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3 and IL-17. Clin Cancer Res 14(24):8314–8320 Yang DS, Galatowicz G, Calder VL et al (2009) Upregulation of Foxp3 expression by recombinant interferon-alpha therapy in Behcet’s disease. ARVO Poster No. 1535